Security
Kodiak Sciences Inc Common Stock · KOD
KODNASDAQCommon stockCurrentCIK 1468748Updated Oct 4, 2026
Name history
Oligasis, LLC · through Jul 28, 2009
KOD price & chart
Loading TradingView…
NASDAQ:KOD on TradingView ↗About the company
Kodiak (NASDAQ: KOD) is a precommercial biotechnology company and a leader in retinal medicines development. We plan to file a biologics license application (BLA) for Zenkuda in the fourth quarter of 2026. We believe Zenkuda is a potential new first-in-class investigational therapy for patients with wet age-related macular degeneration (wAMD), diabetic retinopathy (DR) and macular edema following retinal vein occlusion (RVO). In the recent DAYBREAK Phase 3 study comparing Zenkuda with standard of care aflibercept, patients treated with Zenkuda showed strong immediacy of clinical effect through the loading phase, comparable vision gains and fluid control through the one-year primary endpoint, with a majority of patients treated on an every 6 month dosing interval using a strict treat-to-dryness real world retreatment approach. We also remain on track to announce topline data in December 2026 for KSI-101 in the Phase 3 PEAK study in patients with macular edema secondary to inflammation (MESI), in which KSI-101 is being evaluated for superiority against sham-treated patients. We are planning to file a BLA for KSI-101 in the second quarter of 2027. Looking to Zenkuda and KSI-101, we ha…
In the news
4 Explosive Stories Enter the Investor Spotlight ↗
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares News provided by Kodiak Sciences Inc. Dec 18, 2025, 20:26 ET Share this article Share to X Share this article Share to X PALO ALTO, Calif. , ↗
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock News provided by Kodiak Sciences Inc. Dec 16, 2025, 22:55 ET Share this article Share to X Share this article Share to X PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a precommercial ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 351,533,000Source | 335,578,000Source | 479,372,000Source | 666,628,000Source |
| Property, Plant and Equipment, NetUSD | 85,258,000Source | 102,222,000Source | 120,482,000Source | 56,384,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 209,862,000Source | 168,074,000Source | 285,507,000Source | 190,433,000Source |
| Assets, CurrentUSD | 214,816,000Source | 171,936,000Source | 289,309,000Source | 486,005,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,954,000Source | 3,862,000Source | 3,802,000Source | 7,072,000Source |
| Operating Lease, Right-of-Use AssetUSD | 36,606,000Source | 46,508,000Source | 54,541,000Source | 59,369,000Source |
| Other Assets, NoncurrentUSD | 8,669,000Source | 8,728,000Source | 8,716,000Source | 58,546,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 194,150,000Source | 185,290,000Source | 213,591,000Source | 230,461,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 5,000Source | 5,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,558,705,000Source | -1,328,738,000Source | -1,152,531,000Source | -892,040,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 0Source | -1,307,000Source |
| Stockholders' Equity Attributable to ParentUSD | 157,383,000Source | 150,288,000Source | 265,781,000Source | 436,167,000Source |
| Additional Paid in Capital, Common StockUSD | 1,716,082,000Source | 1,479,021,000Source | 1,418,307,000Source | 1,329,509,000Source |
| Liabilities and EquityUSD | 351,533,000Source | 335,578,000Source | 479,372,000Source | 666,628,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 45,533,000Source | 25,573,000Source | 41,729,000Source | 52,496,000Source |
| Operating Lease, Liability, CurrentUSD | 12,063,000Source | 10,628,000Source | 9,770,000Source | 9,926,000Source |
| Accounts Payable, CurrentUSD | 12,863,000Source | 3,915,000Source | 13,608,000Source | 9,130,000Source |
| Operating Lease, Liability, NoncurrentUSD | 47,117,000Source | 59,717,000Source | 71,862,000Source | 77,807,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 0Source | 162,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 20,607,000Source | 11,030,000Source | 18,351,000Source | 33,440,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 58,863,000Source | 60,213,000Source | 88,556,000Source | 106,033,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 8,070,000Source | -9,693,000Source | 5,597,000Source | 1,660,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -136,008,000Source | -117,319,000Source | -154,183,000Source | -206,459,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -506,000Source | -755,000Source | 249,226,000Source | -336,513,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 506,000Source | 375,000Source | 41,350,000Source | 37,021,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 178,302,000Source | 501,000Source | 31,000Source | 1,895,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 0Source | 13,000Source | 18,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 58,863,000Source | 60,213,000Source | 88,556,000Source | 106,033,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | 0Source |
| DepreciationUSD | 18,328,000Source | 18,710,000Source | 18,298,000Source | 3,796,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -1,000,000Source | 300,000Source | 100,000Source | -300,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | -355,000Source | 0Source | 616,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | 0Source | -2,000Source | — |
| General and Administrative ExpenseUSD | 52,015,000Source | 60,754,000Source | 71,023,000Source | 73,788,000Source |
| Income Tax Expense (Benefit)USD | 52,000Source | 20,000Source | 33,000Source | 33,000Source |
| Investment Income, InterestUSD | 4,517,000Source | 11,148,000Source | 16,733,000Source | 7,071,000Source |
| Net Income (Loss) Attributable to ParentUSD | -229,967,000Source | -176,207,000Source | -260,491,000Source | -333,823,000Source |
| Operating ExpensesUSD | 234,388,000Source | 186,849,000Source | 277,321,000Source | 341,379,000Source |
| Other Nonoperating Income (Expense)USD | -96,000Source | -506,000Source | 110,000Source | 503,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 5,162,000Source | 394,000Source | 60,000Source | 1,770,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -234,388,000Source | -186,849,000Source | -277,321,000Source | -341,379,000Source |
| Other Nonoperating Income (Expense)USD | -96,000Source | -506,000Source | 110,000Source | 503,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -229,915,000Source | -176,187,000Source | 260,432,000Source | 333,790,000Source |
| Income Tax Expense (Benefit)USD | 52,000Source | 20,000Source | 33,000Source | 33,000Source |
| Net Income (Loss) Attributable to ParentUSD | -229,967,000Source | -176,207,000Source | -260,491,000Source | -333,823,000Source |
| Earnings Per Share, BasicUSD per share | -4.32Source | -3.35Source | -4.97Source | -6.39Source |
| Earnings Per Share, DilutedUSD per share | -4.32Source | -3.35Source | -4.97Source | -6.39Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 53,208,311Source | 52,583,148Source | 52,414,256Source | 52,249,620Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 53,208,311Source | 52,583,148Source | 52,414,256Source | 52,249,620Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | 20,000Source | 33,000Source | 33,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -1,000,000Source | 300,000Source | 100,000Source | -300,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | -355,000Source | 0Source | 616,000Source |
| General and Administrative ExpenseUSD | 52,015,000Source | 60,754,000Source | 71,023,000Source | 73,788,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -154,535,000Source | -118,783,000Source | -143,256,000Source | -163,240,000Source |
| Interest ExpenseUSD | 0Source | 0Source | 13,000Source | 18,000Source |
| Investment Income, InterestUSD | 4,517,000Source | 11,148,000Source | 16,733,000Source | 7,071,000Source |
| Operating ExpensesUSD | 234,388,000Source | 186,849,000Source | 277,321,000Source | 341,379,000Source |
| Research and Development ExpenseUSD | 182,373,000Source | 126,095,000Source | 206,298,000Source | 267,591,000Source |
Filing attachments
tm2626623d1_ex99-1.htm · SCHEDULE 13D/A · 2026-09-30
Exhibit 99.1 Holder Common Stock Percent of Class Outstanding ────────────────────────────────────────────────────────────────────────────────── 667, L.P. 1,669,727 2.7% Baker Brothers Life Sciences, L.P. 20,191,214 32.1% Total 21,860,941 34.…
Read attachment ↗tm2626623d1_ex99-2.htm · SCHEDULE 13D/A · 2026-09-30
Exhibit 99.2 Name Date Number of Shares Transaction Price/Share Footnote 667, L.P. 9/28/2026 338 Purchase 81.2019 20 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 667, L.P. 9/28/2026 856 Purchase 61.2104 …
Read attachment ↗d185059dex991.htm · 8-K · 2026-09-28
Exhibit 99.1 Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria. Zenkuda (tarcocimab tedromer) met the primary endpoint (p-value of 0.0007) demonstrating meaningful vision gains as well as rapid and sustained retinal drying w…
Read attachment ↗kod-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said V…
Read attachment ↗kod-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Palo Alto, Calif., May 7, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts and our first planned regulatory submission," said …
Read attachment ↗kod-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results PALO ALTO, Calif., March 31, 2026 - Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “Kodiak’s momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advanc…
Read attachment ↗